Lexeo Therapeutics (NASDAQ:LXEO) Given Buy Rating at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Lexeo Therapeutics (NASDAQ:LXEO - Free Report) in a research note published on Tuesday,Benzinga reports. The firm currently has a $25.00 price objective on the stock. Chardan Capital also issued estimates for Lexeo Therapeutics' FY2025 earnings at ($3.10) EPS.

LXEO has been the topic of a number of other reports. Royal Bank of Canada reissued an "outperform" rating and issued a $24.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday, January 21st. Leerink Partners dropped their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research note on Monday, March 24th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $22.80.

Lexeo Therapeutics Price Performance

LXEO stock traded down $0.01 during midday trading on Tuesday, reaching $4.10. 322,531 shares of the stock were exchanged, compared to its average volume of 345,505. Lexeo Therapeutics has a 52 week low of $2.32 and a 52 week high of $19.50. The company has a fifty day moving average price of $4.05 and a 200 day moving average price of $6.56. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The stock has a market capitalization of $136.11 million, a PE ratio of -1.30 and a beta of 3.85.

Remove Ads

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.09. As a group, analysts expect that Lexeo Therapeutics will post -3.14 EPS for the current fiscal year.

Institutional Trading of Lexeo Therapeutics

Institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP lifted its holdings in Lexeo Therapeutics by 48.3% in the 4th quarter. Wellington Management Group LLP now owns 76,981 shares of the company's stock worth $507,000 after buying an additional 25,089 shares during the period. Woodline Partners LP raised its holdings in shares of Lexeo Therapeutics by 0.8% during the fourth quarter. Woodline Partners LP now owns 858,691 shares of the company's stock valued at $5,650,000 after acquiring an additional 6,730 shares in the last quarter. Vestal Point Capital LP lifted its stake in Lexeo Therapeutics by 41.2% in the fourth quarter. Vestal Point Capital LP now owns 1,200,000 shares of the company's stock worth $7,896,000 after acquiring an additional 350,000 shares during the period. Point72 Asset Management L.P. boosted its holdings in Lexeo Therapeutics by 102.5% in the fourth quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company's stock valued at $4,937,000 after acquiring an additional 379,828 shares in the last quarter. Finally, Millennium Management LLC increased its position in Lexeo Therapeutics by 282.5% during the 4th quarter. Millennium Management LLC now owns 141,951 shares of the company's stock valued at $934,000 after purchasing an additional 104,837 shares during the period. Hedge funds and other institutional investors own 60.67% of the company's stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.